Correction to: Primary headaches during lifespan.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Migraine resolution in a patient receiving CoxThe Journal of the Canadian Chiropractic Association · 2025
   Article
2. Efficacy and safety of the Chaixiong Qiwei granule for tension-type headache: study protocol for a randomised controlled trial.BMJ open · 2023
   Article
3. Current Evidence on Potential Uses of MicroRNA Biomarkers for Migraine: From Diagnosis to Treatment.Molecular diagnosis & therapy · 2019
   Review

Corrections and comments

• Erratum for
  Primary headaches during lifespan.2019

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract